Maria Chiara Magnone | Chief Scientific Officer
Abiologics

Maria-Chiara (Chiara) Magnone is Chief Scientific Officer at Abiologics, a Flagship Pioneering company leveraging generative AI and chemical synthesis to develop therapeutics beyond the limits of biology. At Abiologics she is leading the company’s scientific strategy, platform and pipeline, focused on the development of a new generation of protein therapeutics called Synteins™, mini-proteins made of D-amino acids.

Chiara has extensive experience across various stages of drug development and a wide range of therapeutic areas.

Prior to Abiologics she was at from Johnson & Johnson (J&J), where she was initially Vice President of Kidney Disease Research and Boston Site Head, and more recently Head of Discovery for the Cardiovascular, Metabolic, Retina and Pulmonary Hypertension therapeutic area. During her time at J&J, she led efforts to develop the kidney disease area strategy and pipeline through internal programs and external asset acquisition, and played a key role in advancing several programs to clinical candidate selection. Prior to J&J, she served as Head of Translational Sciences at AstraZeneca, where she led the establishment and implementation of the translational strategy across the cardiovascular, metabolism, and renal portfolio. Chiara began her career in drug discovery and early development and held positions of increasing responsibility at Roche, Novartis and Serono in discovery and development in metabolism and neuroscience.    

Chiara’s work has resulted in publications in Science Translational Medicine, Circulation, Cell Reports, Diabetes Care, and the Journal of the American Society of Nephrology.

Chiara is a biologist by training and completed her Ph.D. in Neurobiology and Neurophysiology at the University of Ferrara (IT) and her post-doc at the University of Fribourg (CH), working on neural and metabolic aspects of circadian rhythms.